| NCT Number | NCT07465029 |
| Lead Sponsor | Bristol-Myers Squibb |
| Conditions | Lower-risk Myelodysplastic Syndromes (TD LR-MDS) |
| Enrollment | 1,300 participants |
| Start Date | 2026-02-02 |
| Primary Completion | 2026-03-31 (estimated) |
| Study Completion | 2026-05-31 (estimated) |
| Updated on ClinicalTrials.gov | 2026-03-11 |